| Novel |
FGF2
|
fibroblast growth factor 2 |
- PI3K Cascade
- PIP3 activates AKT signaling
- Signaling by activated point mutants of FGFR1
- Signaling by activated point mutants of FGFR3
- FGFR4 ligand binding and activation
- FGFR1b ligand binding and activation
- FGFR3c ligand binding and activation
- FGFR1c ligand binding and activation
- FGFR2c ligand binding and activation
- FGFR2b ligand binding and activation
- Activated point mutants of FGFR2
- Constitutive Signaling by Aberrant PI3K in Cancer
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- Phospholipase C-mediated cascade: FGFR1
- Phospholipase C-mediated cascade; FGFR2
- Phospholipase C-mediated cascade; FGFR3
- Phospholipase C-mediated cascade; FGFR4
- Downstream signaling of activated FGFR1
- SHC-mediated cascade:FGFR1
- PI-3K cascade:FGFR1
- FRS-mediated FGFR1 signaling
- PI-3K cascade:FGFR2
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- PI-3K cascade:FGFR3
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- PI-3K cascade:FGFR4
- Negative regulation of FGFR1 signaling
- Negative regulation of FGFR2 signaling
- Negative regulation of FGFR3 signaling
- Negative regulation of FGFR4 signaling
- Signaling by FGFR2 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- FGFRL1 modulation of FGFR1 signaling
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by FGFR2 IIIa TM
- Formation of intermediate mesoderm
- Formation of the nephric duct
- TGFBR3 regulates FGF2 signaling
- Developmental Lineage of Multipotent Pancreatic Progenitor Cells
|
- Sucralfate
- Pentosan polysulfate
- Heparin
- 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
- N,O6-Disulfo-Glucosamine
- 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
- ABT-510
|
|
|
CD53
|
CD53 molecule |
|
|
|
|
FOXK2
|
forkhead box K2 |
|
|
|
|
IFNA1
|
interferon alpha 1 |
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- TRAF6 mediated IRF7 activation
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Factors involved in megakaryocyte development and platelet production
- Evasion by RSV of host interferon responses
|
|
|
|
IL2RA
|
interleukin 2 receptor subunit alpha |
- RAF/MAP kinase cascade
- RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
- Interleukin-2 signaling
- Interleukin receptor SHC signaling
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
- Inolimomab
- Camidanlumab tesirine
|
- Type I diabetes mellitus
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
IL2RB
|
interleukin 2 receptor subunit beta |
- RAF/MAP kinase cascade
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Interleukin receptor SHC signaling
|
- Denileukin diftitox
- Aldesleukin
- Basiliximab
- Daclizumab
|
|
|
IL2RG
|
interleukin 2 receptor subunit gamma |
- Interleukin-7 signaling
- Interleukin-7 signaling
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Interleukin receptor SHC signaling
- STAT3 nuclear events downstream of ALK signaling
|
- Denileukin diftitox
- Aldesleukin
- Resatorvid
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
NGFR
|
nerve growth factor receptor |
- Axonal growth inhibition (RHOA activation)
- NRAGE signals death through JNK
- p75NTR negatively regulates cell cycle via SC1
- Ceramide signalling
- Regulated proteolysis of p75NTR
- NFG and proNGF binds to p75NTR
- NADE modulates death signalling
- NRIF signals cell death from the nucleus
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- Axonal growth stimulation
|
|
|
|
S100A6
|
S100 calcium binding protein A6 |
|
- Calcium citrate
- Calcium Phosphate
- Calcium phosphate dihydrate
|
|
|
SHC1
|
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|